Episode

Key Insights from Attending ASH 2025

Podcast: Treating Blood Cancers
Published: Jan 13, 2026
Duration seconds: 2031
Processing state: not_requested
Canonical source: https://treatingbloodcancers.org/e111/?utm_source=rss&utm_medium=rss&utm_campaign=e111
Audio: https://media.blubrry.com/treating_blood_cancers/content.blubrry.com/treating_blood_cancers/TBC_E111-Lore_Gruenbaum-ASH_Highlights_2025_mixdown_Production.mp3
JSON: /v1/public/podcasts/treating-blood-cancers-14318/episodes/key-insights-from-attending-ash-2025
Markdown: /podcast/treating-blood-cancers-14318/key-insights-from-attending-ash-2025.md

Actions

POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/key-insights-from-attending-ash-2025/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/treating-blood-cancers-14318/key-insights-from-attending-ash-2025.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients